George L King Selected Research

Protein Kinase C

10/2017	Regulation of Macrophage Apoptosis and Atherosclerosis by Lipid-Induced PKCδ Isoform Activation.
3/2016	PKCδ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts.
5/2015	PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis.
8/2013	Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-β isoform in the endothelium.
8/2013	Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells.
4/2011	Glomerular-specific protein kinase C-β-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity.
2/2011	New perspectives on diabetic vascular complications: the loss of endogenous protective factors induced by hyperglycemia.
4/2010	Activation of protein kinase C isoforms and its impact on diabetic complications.
1/2010	Role of protein kinase C in diabetic complications.
6/2007	The role of protein kinase C activation and the vascular complications of diabetes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George L King Research Topics

Disease

26	Hyperglycemia 01/2022 - 09/2002
26	Insulin Resistance 01/2022 - 03/2003
13	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 11/2004
10	Atherosclerosis 01/2022 - 04/2010
10	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2019 - 01/2002
8	Obesity 01/2022 - 03/2006
7	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 07/2004
7	Inflammation (Inflammations) 01/2019 - 04/2005
6	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 12/2008
6	Type 2 Diabetes Mellitus (MODY) 01/2022 - 06/2007
6	Diabetes Complications 10/2017 - 12/2004
5	Ischemia 10/2021 - 01/2002
5	Hyperinsulinism (Hyperinsulinemia) 01/2018 - 05/2012
5	Fibrosis (Cirrhosis) 10/2015 - 09/2002
4	Hypoxia (Hypoxemia) 01/2021 - 01/2002
4	Diabetes Mellitus 10/2017 - 07/2004
4	Dyslipidemias (Dyslipidemia) 01/2013 - 05/2007
4	Heart Failure 11/2012 - 09/2002
4	Retinal Neovascularization 10/2006 - 01/2002
3	Body Weight (Weight, Body) 01/2022 - 03/2009
3	Hypertrophy 03/2009 - 11/2006
2	Hyperplasia 01/2019 - 01/2017
2	Hyperlipidemias (Hyperlipidemia) 01/2018 - 10/2017
2	Atherosclerotic Plaque (Atheroma) 01/2018 - 05/2015
2	Mitochondrial Diseases (Mitochondrial Disease) 06/2017 - 01/2007
2	Wounds and Injuries (Trauma) 03/2016 - 01/2016
2	Weight Gain 01/2014 - 06/2006
2	Diabetic Angiopathies (Diabetic Angiopathy) 01/2013 - 06/2007
2	Albuminuria 11/2012 - 07/2012
2	Cardiomyopathies (Cardiomyopathy) 04/2010 - 09/2002
2	Chronic Disease (Chronic Diseases) 06/2007 - 05/2007
1	Arteritis 01/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Pathologic Processes 10/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 10/2021
1	Reperfusion Injury 10/2021
1	Neoplasms (Cancer) 01/2021
1	Cognitive Dysfunction 01/2021
1	Periodontitis 01/2019
1	Hemorrhage 01/2019

Drug/Important Bio-Agent (IBA)

38	Insulin (Novolin)FDA Link 01/2022 - 01/2002
21	Protein Kinase CIBA 10/2017 - 09/2002
19	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2002
17	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2002
13	Protein Isoforms (Isoforms)IBA 10/2017 - 01/2002
11	CytokinesIBA 01/2019 - 01/2002
10	Retinaldehyde (Retinal)IBA 01/2021 - 01/2002
10	LipidsIBA 01/2019 - 08/2008
6	Apolipoproteins E (ApoE)IBA 01/2022 - 05/2012
6	Protein Kinase C betaIBA 03/2009 - 01/2002
5	Proteins (Proteins, Gene)FDA Link 10/2021 - 07/2004
5	Biomarkers (Surrogate Marker)IBA 11/2019 - 05/2007
4	Insulin ReceptorIBA 01/2022 - 04/2006
4	EnzymesIBA 01/2022 - 04/2010
4	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2018 - 03/2006
4	Nonesterified Fatty Acids (NEFA)IBA 01/2016 - 12/2004
4	Protein Kinases (Protein Kinase)IBA 08/2013 - 07/2004
4	AntioxidantsIBA 01/2013 - 03/2003
4	Platelet-Derived Growth FactorIBA 09/2012 - 11/2009
3	Pyruvate KinaseIBA 01/2022 - 06/2017
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022 - 03/2006
3	C-PeptideIBA 01/2019 - 05/2012
3	Insulin-Like Growth Factor I (IGF-1)IBA 01/2019 - 06/2003
3	ApolipoproteinsIBA 01/2018 - 05/2010
3	C-Reactive ProteinIBA 06/2014 - 11/2004
3	DiglyceridesIBA 06/2007 - 09/2002
3	Oxidants (Oxidizing Agents)IBA 11/2006 - 11/2002
2	Messenger RNA (mRNA)IBA 01/2022 - 06/2017
2	Endothelin Receptors (Endothelin Receptor)IBA 01/2022 - 05/2016
2	Nitric Oxide Synthase (NO Synthase)IBA 01/2022 - 03/2006
2	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 11/2019 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 01/2018
2	Insulin Receptor Substrate ProteinsIBA 01/2016 - 04/2011
2	Transforming Growth Factors (Transforming Growth Factor)IBA 10/2015 - 11/2012
2	Fatty Acids (Saturated Fatty Acids)IBA 08/2013 - 08/2008
2	Endothelin-1 (Endothelin 1)IBA 08/2013 - 03/2003
2	Angiotensin IIIBA 08/2013 - 04/2005
2	p38 Mitogen-Activated Protein KinasesIBA 07/2012 - 07/2004
2	Advanced Glycation End ProductsIBA 04/2011 - 04/2005
2	Phosphotransferases (Kinase)IBA 03/2009 - 11/2002
2	polyolIBA 06/2007 - 06/2005
2	Transforming Growth Factor beta (TGF-beta)IBA 11/2006 - 09/2002
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2004 - 07/2004
2	Oxygen (Dioxygen)IBA 02/2002 - 01/2002
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2002 - 01/2002
1	arginine methyl esterIBA 01/2022
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2022
1	Oxidoreductases (Dehydrogenase)IBA 10/2021
1	aristolochic acid I (aristolochic acid)IBA 10/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	ChromatinIBA 01/2021
1	Aryldialkylphosphatase (Paraoxonase)IBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	Immunoglobulin G (IgG)IBA 01/2019
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2019
1	PhlorhizinIBA 01/2018
1	salicylhydroxamic acid (SHAM)IBA 01/2018

Therapy/Procedure

4	Therapeutics 10/2021 - 06/2005
3	Glycemic Control 01/2022 - 10/2017